• Cyclophosphamide: Designing Mechanism-Aware Assays

  2026-08-28

  Cyclophosphamide is an alkylating chemotherapeutic agent whose bioactivation, DNA damage, and immune effects require carefully designed assays. This guide connects experimental parameters with mechanistic interpretation and distinguishes cyclophosphamide evidence from topotecan-based oncology findings.

• MTT Assay Workflow for Cell Viability

  2026-08-28

  Build a reproducible MTT workflow for metabolic activity measurement, cell proliferation studies, and cytotoxicity screening. The practical framework connects MTT readouts with the MALAT1/miR-135b-5p/GPNMB findings in a Parkinson’s disease cell model while showing where orthogonal assays remain essential.

• ST3GAL1, Sialylation, and F. nucleatum Adhesion

  2026-08-27

  This study identifies ST3GAL1-dependent sialylation as a host-cell determinant of Fusobacterium nucleatum adhesion to colorectal cancer cells. It further connects persistent bacterial colonization with an H3K27ac–ANGPTL4 pathway, offering a mechanistic framework for understanding how tumor glycosylation may support intratumoral microbiota retention.

• Toremifene Assays: From ER Biology to Bone Metastasis

  2026-08-27

  Toremifene offers a research framework for connecting estrogen receptor modulation with prostate cancer cell phenotypes. This article translates the TSPAN18–STIM1 findings into practical assay decisions while separating established evidence from testable hypotheses.

• TAK1–YAP Signaling in Gastric Cancer Stem Cells

  2026-08-26

  The reference study identifies TGFβ-activated kinase 1 (TAK1) as an IL-6-responsive regulator of YAP stability in gastric cancer stem cells. Its findings connect TAK1–YAP signaling with SOX2/SOX9 expression, cancer stem cell self-renewal, and tumorigenesis, providing a mechanistic framework for studying gastric cancer progression.

• Nanoparticle mRNA Delivery Reverses Trastuzumab Resistance

  2026-08-26

  The reference study developed a tumor-microenvironment pH-responsive nanoparticle system for systemic delivery of PTEN mRNA to trastuzumab-resistant breast cancer. Its central finding is that restoring PTEN expression can inhibit persistently active PI3K/Akt signaling, providing a mechanistically targeted strategy for re-sensitizing resistant tumors to trastuzumab.

• Serine/Glycine Restriction and PD-L1 Lactylation

  2026-08-25

  The reference study shows that a serine/glycine-free diet can restrain colorectal cancer growth while increasing cytotoxic T-cell activity, but may also promote immune escape through PD-L1 lactylation. Its combination of mechanistic tumor studies and an early clinical feasibility study provides a useful framework for evaluating nutrient-restricted diets alongside immune checkpoint therapy.

• Direct Mouse Genotyping Kit Plus for Macrophage Studies

  2026-08-25

  Connect rapid, purification-free mouse genotyping with lineage-tracing, transgene, and knockout workflows in immuno-oncology research. This practical guide shows how to use direct lysates, high-fidelity PCR, and dye-enabled electrophoresis while avoiding common inhibitors and genotype miscalls.

• Estradiol: From Receptor Bias to Organ-Level Assays

  2026-08-24

  Estradiol and 17 beta-estradiol are powerful tools for connecting estrogen receptor signaling with tissue-level biology. This article presents an assay-interpretation framework that links receptor context, autophagy, and organ protection without confusing correlation with mechanism.

• Meropenem Trihydrate: From Mechanism to Translation

  2026-08-24

  Meropenem trihydrate can serve as more than a broad-spectrum antibacterial control. By pairing its penicillin-binding protein mechanism with LC-MS/MS metabolomics, researchers can connect resistance phenotypes to measurable metabolic states and build more translational infection models.

• Standardized Whole-Blood Immunometabolism Assay

  2026-08-23

  Zhao and colleagues present a standardized whole-blood stimulation protocol for testing how metabolic interventions shape human immune responses. By combining defined immune stimuli, pathway-directed inhibitors, and cytokine quantification, the workflow supports reproducible immunometabolism research while preserving the cellular complexity of whole blood.

• EGTA for Calcium Signaling Assay Design

  2026-08-22

  EGTA, or egtazic acid, offers a practical way to test whether extracellular calcium drives neuronal injury, synaptic excitation, inflammation, or apoptosis. This workflow-focused guide connects selective calcium chelation with electrophysiology, cell viability assays, and troubleshooting strategies for reproducible experiments.

• Pifithrin-α: p53 Inhibitor Evidence & Workflow

  2026-08-22

  Pifithrin-α is a p53 inhibitor used to test p53-dependent apoptosis, growth arrest, and ferroptosis mechanisms. Evidence from irradiated cellular models and a deltamethrin neurotoxicity study supports mechanistic use, but does not establish clinical cancer therapy side effect mitigation.

• Fraxinellone Activates PINK1/Parkin Mitophagy in IBD

  2026-08-21

  The reference study identifies fraxinellone as a potential modulator of mitochondrial quality control in inflammatory bowel disease. Using DSS and LPS injury models, molecular docking, CETSA, and PINK1 knockdown, the authors link fraxinellone protection to PINK1/Parkin-dependent mitophagy rather than to nonspecific anti-inflammatory activity alone.

• BCECF for Extracellular pH Assays

  2026-08-20

  BCECF provides a ratiometric way to connect extracellular acidity with ion transport, macrophage function, and disease-model biology. This practical guide explains how to calibrate the probe, integrate it with efferocytosis workflows, and avoid confusing extracellular pH changes with intracellular readouts.

8042 records 1/537 page Next 12345 下5页 Last page